Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

Arquivos deste item

Este item aparece na(s) seguinte(s) coleção(s)

Buscar no OPI



Navegar

Minha conta

Estatísticas